PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Dexmedetomidine shortens agitation, not delirium, in non-intubated ICU patients

dexmedetomidinealpha-2 agonisthaloperidolhyperactive deliriumagitationICU deliriumsedationnon-intubatedrandomized controlled trial4D trialRASSCAM-ICUantipsychotic stewardshipcritical care Critical Care / ICU

Background Information

Dexmedetomidine shows promise for delirium in non-intubated ICU patients.

Managing hyperactive delirium in non-intubated ICU patients is challenging, and current options are limited by side effects. Dexmedetomidine significantly reduced delirium symptoms compared to placebo, with fewer adverse effects reported. While promising, further studies are needed to confirm these findings across diverse patient groups and settings. Dexmedetomidine may be effective and safer for hyperactive delirium in non-intubated ICU patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Godet T, Louis C, Rieu B, De Jong A, Couhault P, Pradel G, Tête H, Bourguignon N, Borao L, Jabaudon M, Futier E, Jaber S, Pereira B, Chanques G, Constantin JM, 4D study group

Citation: Godet T, Louis C, Rieu B, et al. Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial. Intensive care medicine. 2025;51(12):2305-2317. doi:10.1007/s00134-025-08135-1

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.